Alector

ALEC

Market cap $198M

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that Neil Berkley, who has served as Alector's Chief Business Officer (CBO) since March 2024, and CBO and Interim Chief Financial Officer (CFO) since June 2025, has been appointed CFO, effective December 10, 2025. Mr. Berkley will continue to serve as CBO.

Alector, Inc. (ALEC) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a fireside chat at the Bank of America CNS Therapeutics Conference, being held virtually on Monday, December 8, 2025, at 2:25 pm ET.

LOS ANGELES, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alector, Inc. (“Alector” or “the Company”) (NASDAQ: ALEC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

LOS ANGELES, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alector, Inc. (“Alector” or “the Company”) (NASDAQ: ALEC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ALEC stock plunges after its dementia candidate fails to slow disease progression in a late-stage study, prompting job cuts and a strategic pipeline shift.

LOS ANGELES--(BUSINESS WIRE)---- $ALEC--ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm.

Alector (ALEC) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.43 per share a year ago.

Selected lead candidates AL137 for the company's Alector Brain Carrier (ABC)-enabled anti-amyloid beta antibody in Alzheimer's disease, and AL050 for its ABC-enabled GCase enzyme replacement therapy in Parkinson's disease; both advancing toward IND-enabling studies

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.